# US 2021/0171475 A1 · Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171475 A1
- Document ID: US20210171475A1
- Status: Published application
- Kind: A1
- Application number: 17/272,268
- Filed: 2019-08-30
- Published: 2021-06-10
- Earliest claimed: 2018-08-31
- Assignees: UCL Business PLC
- Applicants: Ucl Business Ltd
- Inventors: Paul Vincent Fish; William Mahy; Nicky John Willis; Hannah Woodward; Benjamin N Atkinson; Elliott D Bayle; James Sipthorp; Edith Yvonne Jones; Yuguang Zhao; Luca Vecchia; Reinis Reinholds Ruza
- Web page: https://patentgrep.com/patent/US20210171475A1

## CPC

- C07D 249/06: with aryl radicals directly attached to ring atoms
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 213/16: containing only one pyridine ring
- C07D 213/64: attached in position 2 or 6
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/20: One oxygen atom attached in position 3 or 5
- C07D 233/56: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 237/14: Oxygen atoms
- C07D 239/34: One oxygen atom
- C07D 239/36: as doubly bound oxygen atom or as unsubstituted hydroxy radical
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 249/12: Oxygen or sulfur atoms
- C07D 257/04: Five-membered rings
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 271/07: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D 271/10: 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D 271/113: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D 285/06: 1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
- C07D 285/13: Oxygen atoms
- C07D 285/135: Nitrogen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)

## Claims

### Claim 1

A compound of formula (I):
where Ar is C5 heteroaryl or a C6 N-containing heteroaryl, optionally substituted by a group selected from
a) OH, SH, NH2, OMe, SMe, NHMe, NMe2, OEt, NHCN, Me;
b) CN, CO2H;
c) SO2Me, SO3−Na+;
d) CH2Q1, where Q1 is selected from OH, OMe, Cl, CN, NHCOMe, SO3H, NRN1RN2, where RN1 and RN2 are either H or Me;
e) C2-3 alkyl substituted by OH;
where a N-ring heteroatom may additional bear a methyl group; and
X1 is CR1;
X2 is CR2;
X3 is CR3;
X5 is CR5;
two of R1, R2, R3, R4 and R5 are H, two of R1, R2, R3, R4 and R5 are Cl and one of R1, R2, R3, R4 and R5 is CF3.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein Ar is C5 heteroaryl, with an optional substituent.

### Claim 3 (depends on 2)

A compound according to claim 2, wherein Ar is selected from:
where subst represents the substituent.

### Claim 4 (depends on 3)

A compound according to claim 3, wherein Ar is selected from:
where subst represents the substituent.

### Claim 5 (depends on 2)

A compound according to claim 2, wherein there are three heteroatoms in the ring.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein the substituent is selected from OH, OMe, OEt and NHCN.

### Claim 7 (depends on 6)

A compound according to claim 6, wherein the substituent is OH.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein the substituent is CH2OH.

### Claim 9 (depends on 1)

A compound according to claim 1, wherein there is no substituent on Ar.

### Claim at position 10

10-20. (canceled)

### Claim 21 (depends on 1)

A compound according to claim 1, wherein R2 is Cl, R3 is CF3 and R4 is Cl.

### Claim at position 12

22-24. (canceled)

### Claim 25 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable excipient.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A compound according to claim 1, wherein:
(i) Ar is
where subst represents the optional substituent;
(ii) Ar is
and:
a. at least 2 of R1 to R5 are not H and one of R1 to R5 is not Me; and
R1, R2, R3, R4 and R5 (if present) are independently selected from:
i) H;
ii) C3-6 cycloalkyl, with an optional O ring atom;
ii) CN, NMe2, NO2;
iv) OCH2Q2, where Q2 is selected from C3-6 cycloalkyl and phenyl;
v) CH2OH;
vi) NRN6RN7, where RN6 and RN7 together form a C4-6heterocyclyl group optionally substituted with 1 to 2 groups selected from halo, C1-3 alkyl, cyano and oxetanyl;
or two adjacent groups of R1 to R4 together form a group -Q3-(CRC2)n-Q4-, where Q3 is selected from NRN3 and O, where RN3 is selected from H, C1-3 alkyl, cyclopropylmethyl and COMe; Q4 is NRN4, O or a single bond, where RN4 is selected from H, C1-3 alkyl, cyclopropylmethyl and COMe; each RC is independently H, F or Me or two Rc which are attached to the same atom can be linked together to form a C3-5cycloalkyl; and n is 1, 2 or 3;
or two adjacent groups of R1 to R5 form a fused benzene or C5-6 heteroaromatic ring with the phenyl group, which itself is optionally substituted by a C1-2 alkyl group;
b. at least 1 of R1 to R4 (if present) is C3-6 cycloalkyl;
c. two adjacent groups of R1 to R4 together form a group -Q3-(CH2)n-Q4-, where Q3 is selected from NRN3 and O, where RN3 is selected from H, Me and COMe; Q4 is a single bond; and n is 1 or 2;
(iii) Ar is
subst is selected from:
a) H;
b) NH2, SH, OMe, SMe;
c) CN, CO2H, COmorph;
d) SO2Me;
e) C2-3 alkyl substituted by OH;
and at least 2 of R1 to R4 are not H;
(iv) Ar is
or
(v) Ar is
and R3 is iPr.

### Claim 28 (depends on 1)

A compound according to claim 1, wherein the compound is selected from:
4-[2,4-dichloro-3-(trifluoromethyl)phenyl]-1H-triazole (306);
2-(2,4-dichloro-3-(trifluoromethyl)phenyl)-5-(methoxy-d3)-1,3,4-oxadiazole (241);
2-(2,4-dichloro-3-(trifluoromethyl)phenyl)-5-ethoxy-1,3,4-oxadiazole (242);
4,5-dideuterio-1-[2,4-dichloro-3-(trifluoromethyl)phenyl]triazole (308);
5-[2,4-dichloro-3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-ol (261);
2-(2,4-dichloro-3-(trifluoromethyl)phenyl)-5-methoxy-1,3,4-oxadiazole (243);
1-[2,4-dichloro-3-(trifluoromethyl)phenyl]triazole (295); and
N-(5-(2,4-dichloro-3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)cyanamide, ammonia salt (246).

### Claim 29

1-[2,4-dichloro-3-(trifluoromethyl)phenyl]triazole (295).

### Claim 30 (depends on 1)

A method of treatment of a disease or disorder ameliorated by the inhibition of Notum, comprising administering to a patient in need of treatment, a compound as defined in claim 1.

### Claim 31 (depends on 30)

A method according to claim 30, wherein the disease or disorder is a neurodegenerative disorder or a central nervous system disorder.

### Claim 32 (depends on 30)

A method according to claim 30, wherein the disease or disorder is a neurodegenerative disease, and the neurodegenerative disease is Alzheimer's disease.
